US2020016243A1PendingUtilityA1

Treatment of infection by human enterovirus d68

66
Assignee: ANSUN BIOPHARMA INCPriority: Sep 17, 2014Filed: Jun 24, 2019Published: Jan 16, 2020
Est. expirySep 17, 2034(~8.2 yrs left)· nominal 20-yr term from priority
Inventors:Ronald B. Moss
A61K 38/164C07K 14/70503C12Y 302/01018C07K 14/485C07K 14/5421C12N 9/2402C12N 7/00A61K 38/46C07K 14/522C07K 14/8128C07K 2319/20Y02A50/30
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure provides compositions and methods for treating an infection by EV-D68. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by EV-D68.

Claims

exact text as granted — not AI-modified
1 . A method of treating infection by EV-D68 in a patient, the method comprising administering to the patient an effective amount of an agent having sialidase activity. 
     
     
         2 .- 23 . (canceled)

Join the waitlist — get patent alerts

Track US2020016243A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.